Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

F. Schlenk, Richard; Weber, Daniela; Fiedler, Walter; R. Salih, Helmut; Wulf, Gerald; Salwender, Hans; Schroeder, Thomas; Kindler, Thomas; Lübbert, Michael; Wolf‎, Dominik; Westermann, Jörg; Kraemer, Doris; S. Götze, Katharina; Horst, Heinz‐August; Krauter, Jürgen; Girschikofsky, Michael; Ringhoffer, Mark; Südhoff, Thomas; Held, Gerhard; Derigs, Hans‐Günter; Schroers, Roland; Greil, Richard; Grießhammer, Martin; Lange, Elisabeth; Burchardt, Alexander; M. Martens, Uwe; Hertenstein, Bernd; Marretta, Lore; Heuser, Michael; Thol, Felicitas; I. Gaidzik, Verena; Herr, Wolfgang; Krzykalla, Julia; Benner, Axel; Döhner, Konstanze; Ganser, Arnold; Paschka, Peter; Döhner, Hartmut

doi:10.1182/blood-2018-08-869453

Public

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

Published in Blood • Dec 18, 2018

Authors:

Richard F. Schlenk

Daniela Weber

Walter Fiedler

Abstract

Abstract Patients with acute myeloid leukemia (AML) and a FLT3 internal tandem duplication (ITD) have poor outcomes to current treatment. A phase 2 hypothesis-generating trial was conducted to determine whether the addition of the multitargeted kinase inhibitor midostaurin to intensive chemotherapy ...

Subject

Midostaurin

Medicine

Myeloid leukemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!